Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Waverley Pharma Inc

WAVE.V ✗ NOT COMPLIANT ☆ Track — members

TSX Venture · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.01

▲ +0.00%

Market Cap $581.48K · Vol 1.00K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$581.48K

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

1.36

vs Market

52W High

$0.03

63.16% below

52W Low

$0.01

51.98% above

Volume

1.00K

Avg 1.08K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

25.10%

Public shares

Shariah Compliance8 STANDARDS

✗ Waverley Pharma Inc (WAVE.V) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does WAVE.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-40.00%

+50.00%

+0.00%

YTD

-25.00%

+0.00%

-58.45%

-86.96%

Financials & Valuation

TTM · Annual

Total Revenue	$983.39K
Net Income	$-363,750.00
Revenue Growth (YoY)	-26.63%
Gross Margin	38.06%
Operating Margin	-25.88%
Net Profit Margin	-36.99%
ROE	N/A
ROA · ROIC	-30.25% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.80
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	54.00M

Technical Indicators

50-Day SMA	$0.01
200-Day SMA	$0.01
RSI (14)	50.00
Beta	1.36
52-Week High	$0.03
52-Week Low	$0.01

Volume Today	1.00K
Avg Daily Volume (30D)	1.08K
Relative Volume	0.92x
Volatility (10D)	0.00
Volatility (30D)	287.99
Free Float	25.10%

Analyst Consensus

N/A

Current Price $0.01

Mean Target N/A

52W Low$0.01 52W High$0.03

Current

Target

$0.01 $0.03

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX Venture

FIGIBBG00HTFNC05

ISINCA94357L1058

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.